BIOMARKER FOR MEASUREMENT OF RESPONSE AND PROGNOSIS OF TRIPLE-NEGATIVE BREAST CANCER TO ANTICANCER AGENT

摘要

The present invention discloses a biomarker capable of predicting the therapeutic reactivity and prognosis of triple-negative breast cancer to an anticancer agent, and the use thereof. A marker according to the present invention allows the provision of optimized personal therapeutic methods through correct personalized treatment, thereby contributing to the quality and prolongation of life of patients.